TheraRadar
← Back
Data updated: Sep 20, 2026

PRIOVANT THERAP

Pharma
Pharmaceuticals Execution: Needs Improvement

PRIOVANT THERAP is a pharmaceutical company with 1 FDA-approved products.

2026
Since
1
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
1 Small Molecules

PRIOVANT THERAP's Key Drugs

PRIOVANT THERAP's core commercial portfolio centers on LISRAYA — its most strategically important drugs approved in the last 15 years.

LISRAYA
Approved 2026

PRIOVANT THERAP's Recent FDA Approvals

PRIOVANT THERAP secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

LISRAYA NDA
2026-08-27
brepocitinib tosylate

PRIOVANT THERAP's Therapeutic Areas

Disease areas where PRIOVANT THERAP has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

PRIOVANT THERAP Pipeline Snapshot

Active clinical trials for PRIOVANT THERAP across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Phase 3 Readout Calendar Pro

1 Phase 3 trial with confidence-graded primary completion dates.

Full calendar →
Q4 2028
Oral Brepocitinib
Lichen Planopilaris
Estimated · fresh NCT07532603

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • LISRAYA leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • 1 Phase 3 readout tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 0/2 completed
  • • Speed: N/A months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges